Auxilium Pharmaceuticals Inc (AUXL)

neg -0.06
Today's Range: 36.08 - 36.76 | AUXL Avg Daily Volume: 1,224,600
Last Update: 01/29/15 - 4:00 PM EST
Volume: 3,717,863
YTD Performance: 0.00%
Open: $36.50
Previous Close: $36.53
52 Week Range: $17.10 - $37.93
Oustanding Shares: 51,021,504
Market Cap: 1,942,653,033
6-Month Chart
TheStreet Ratings Grade for AUXL
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 0 0 0 0
Moderate Buy 0 0 0 0
Hold 8 8 8 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 3.00 3.00 3.00 3.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 0.00
Price Earnings Comparisons:
AUXL Sector Avg. S&P 500
0.00 0.00 25.69
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.00% 0.00% 0.00%
Revenue 1.40 0.90 0.23
Net Income -100.00 -0.65 0.00
EPS -100.00 -0.66 0.00
Earnings for AUXL:
Revenue 0.40B
Average Earnings Estimates

Earnings Estimates data is not available for AUXL.

Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
May 28, 2014 | 7:37 AM EDT
AUXL was upgraded to Buy, MKM Partners said. $26 price target. Stock is down 30% since March, but Testim appears to have stabilized and...
Apr 30, 2014 | 7:35 AM EDT
AUXL lowered its number, UBS said. Full year guidance lowered  with shrinking T-gel shrinking and downward pressure on Rx in T-gel...
Mar 06, 2014 | 7:51 AM EST
AUXL was downgraded to Underweight, Morgan Stanley said. Valuation call, based on a $15 price target. 
Jan 23, 2014 | 7:53 AM EST
AUXL was downgraded to Neutral, MKM Partners said. $23 price target. Valuation call, as the stock is up 25% over the past two weeks.
May 03, 2013 | 8:26 AM EDT
AUXL was upgraded from Underweight to Equal-weight, Morgan Stanley said. Risk/reward is more attractive, following a 50% decline since ...
Portfolio Mgr. David Peltier analyzes a volatile, low-dollar drug stock.
Nov 08, 2012 | 8:22 AM EST
Shares of AUXL now seen reaching $29, Jefferies said. Estimates also lowered on Testim miss. Buy rating.
Portfolio David Peltier finds a pharma name that's quietly growing faster than its peers.
Aug 01, 2012 | 8:43 AM EDT
Shares of AUXL now seen reaching $32, Jefferies said. Estimates also raised on first quarter results. Buy rating.
Aug 01, 2012 | 8:38 AM EDT
Shares of AUXL now seen reaching $32, UBS said. Estimates also increased as Testim sales ramp should drive upside. Buy rating.

Columnist Conversations

Foot Locker's (FL) less than expected quarterly earnings set off a round of selling the entire athletic appare...
View Chart »  View in New Window » Gold has met the first upside target off the last setup zon...
View Chart »  View in New Window »
View Chart »  View in New Window »


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.